Archive for the 'Technology' Category
July 29th, 2010 by admin
Milestone payments are becoming an increasingly familiar aspect of many biotech deals, as buyers try to mitigate the risks inherent with big purchases. Take Celgene’s $2.9 billion buyout of Abraxis; the biotech giant set aside $650 million in milestone payments if Abraxis’ key drug Abraxane hit certain goals. “These structures are a great way for buyer and seller to share the risk that’s related to drug development,” says analyst Brett Skolnik. Milestones also encourage buyer and seller to look beyond the merger, making it more likely the deal will be beneficial to both sides in the long term.
Continue reading ‘Milestones Mitigate Risk in Biotech Deals’
July 27th, 2010 by admin
Oncologics, lipid regulators, respiratory agents, antidiabetics and anti-ulcerants are the five largest drug classes by sales. But annual sales are only half the story. Which drug classes are booming, and which have plateaued–or even dropped? IMS Health has released top-line industry data revealing the 15 largest drug classes, and we’ve crunched the numbers to take a closer look at the average sales growth of the 15 largest therapeutic classes over the last five years.
Continue reading ‘Fastest Growing Therapeutic Classes (by Sales)’
July 23rd, 2010 by admin
A group of scientists have demonstrated that specially engineered stem cells could be used to fights off AIDS, successfully testing the approach in mice engineered to develop immune systems similar to humans. The investigators started with the observation that a small group of people who are virtually immune to HIV have disabled CCR5 receptors on their immune cells–a door the virus uses to infect the cells. The scientists engineered stem cells with the ‘door’ essentially locked, then inserted them into the mice, where they developed into immune cells that were able to guard the mice against HIV.
Continue reading ‘Specially Engineered Immune Cells Ward off AIDS’
July 22nd, 2010 by admin
Nigeria is fast-tracking mobile authentication services in its fight against drug counterfeiters. Manufacturers will bear the brunt of the cost, at least initially. The costal country of 150 million is at the forefront of African anti-counterfeiting efforts, thanks largely to a rampant supply of malaria drug fakes. In mid-May, the nonprofit Pedigree Network and computer giant HP launched an authentication trial in Nigeria and Ghana; Nigeria is also conducting tests with Merck using technology from Sproxil.
Continue reading ‘Nigeria Takes on Fake Drugs with New Technology’
July 14th, 2010 by admin
Chang Lu and his chemical engineering research group at Virginia Tech have discovered how to “greatly enhance” the delivery of DNA payloads into cells. The description of their work will be featured on the cover of Lab on a Chip, the premier journal for researchers in microfluidics. Lu’s ultimate goal is to apply this technique to create genetically modified cells for cancer immunotherapy, stem cell therapy and tissue regeneration.
Continue reading ‘New Spin on DNA Delivery: Enhanced Delivery Method of DNA Payloads into Cells’
July 9th, 2010 by admin
For someone with a severe, incurable lung disorder such as cystic fibrosis or chronic obstructive pulmonary disease, a lung transplant may be the only chance for survival. Unfortunately, it’s often not a very good chance. Matching donor lungs are rare, and many would-be recipients die waiting for the transplants that could save their lives.
Continue reading ‘Scientists Grow New Lungs Using ‘Skeletons’ of Old Ones’
June 29th, 2010 by admin
Cytori Therapeutics may need to spend $10 million more than anticipated to get clearance for its first product because of a stricter-than-anticipated regulation. Cytori had laid out $200 million in eight years on the device and was seeking ”fast-track” clearance for the body-tissue repair device. But now it must take the slower regulatory path used for about one in every 10 experimental devices.
Continue reading ‘FDA Imposes Hurdle for Cytori Breast Repair Device’
June 21st, 2010 by admin
Patients recovering from congestive heart failure at a New York hospital are being offered a telemonitoring system to help with medication compliance. The data collected from the system generates an e-diary of patient adherence to the prescribed drug regimen, so clinicians and doctors can monitor compliance at the patient or study group level.
Continue reading ‘RFID System Checks Rx Compliance’
June 18th, 2010 by admin
I’ve always envied people who can get injections without flinching, as somehow, seeing a needle enter the skin gives me the jitters. This is probably the reason intravenous drug abuse has never appealed to me (next to the addiction and death issues, of course). But thanks to Pantec Biosolutions and its Please (Painless Laser Epidermal System) device, getting a jab may no longer require the doctor to chase after a 33-year-old man shrieking down the hospital halls.
Continue reading ‘Forget Needles. ‘Please’ Delivers Drugs via Lasers’
June 17th, 2010 by admin
The scramble to come up with a faster and cheaper way to sequence a genome just got a credible new contender which aims to do the job for the bargain basement rate of $30. The first time scientists sequenced a human genome, the price tag hit $3 billion. That price point has quickly plunged to about $20,000, putting sequencing genomes for the purposes of drug discovery work within the reach of biopharma companies. But this new company, a spinoff from Harvard University dubbed GnuBio, says the trick to bringing sequencing within reach of most people on the planet revolves around deciphering fragments of DNA from droplets streaming through a tiny tube.
Continue reading ‘Genome Sequencing for $30 – A Harvard Spin-off Promise’
